Fibrinolytic response to tumor necrosis factor in healthy subjects by unknown
BriefDefinitive Report
Fibrinolytic Response to Tumor Necrosis Factor in
Healthy Subjects
By Tom van der Poll,*f Marcel Levi,# Harry R . Bullerj
Sander J . H . van Deventer,*$ Jan P. de Boer,S C. Erik Hack,§
and Jan W. ten Cate#
From the 'Department of Internal Medicine and the #Center for Hemostasis, Thrombosis,
Atherosclerosis and Inflammation Research, Academic Medical Center, University ofAmsterdam,
1105 AZ Amsterdam; and the SCentral Laboratory of the Netherlands Red Cross Blood
Transfusion Service and the Laboratory for Experimental and Clinical Immunology, University
of Amsterdam, 1066 CX Amsterdam, The Netherlands
Summary
Tumor necrosis factor (TNF)may be involved in the disturbance ofthe procoagulant-fibrinolytic
balance in septicemia, leading to microvascular thrombosis. To assess the dynamics of the fibrinolytic
response to TNF in humans, we performed a crossover saline-controlled study in six healthy
men, investigating the effects of a bolus intravenous injection of recombinant human TNF (50
Ag/m2 ) on the stimulation and inhibition of plasminogen activation as well as on plasmin
activity and inhibition . TNF induced a brief fourfold increase in the overall plasma plasminogen
activator (PA) activity peaking after 1 h (p < 0.0001), which was associated with rises in the
antigenic levels of urokinase-type plasminogen activator (p< 0.0001) and tissue-type plasminogen
activator (p < 0.0001) . Plasminogen activator inhibitor type I antigen remained unchanged in
the first hour, but showed a rapid eightfold increase thereafter (p < 0.0001), which coincided
with the decrease in PA activity. Generation of plasmin activity in the first hour was signified
by an 11-fold rise in D-dimer levels (p< 0.0001); inhibition of plasmin was reflected by a 36-fold
rise in plasmin-a2 antiplasmin complexes (p < 0.0001), as well as by a transient 16% decrease
in C12-antiplasmin activity (p < 0.01) . In conclusion, TNF induced an early activation of the
fibrinolytic system becoming maximal in 1 h, with a rapid inhibition thereafter. Earlier observations
in the same subjects showed sustained coagulation activation for 6-12 h . The observed disbalance
between the procoagulant and fibrinolytic mechanisms afterTNF injection confirms the in vivo
relevance of the effects of TNF on vascular endothelium in vitro and may explain the tendency
towards microvascular thrombosis in septicemia .
D
isseminated intravascular coagulation is a serious and
frequent complication of septicemia . In septicemia, ac-
tivation ofthe coagulation cascade is accompanied by a biphasic
change in the fibrinolytic system involving initial stimula-
tion and subsequent inhibition of plasminogen activation (1) .
The net result of these concomitant coagulative and fibrino-
lytic responses in septic patients is microvascular thrombosis .
In recent years, evidence has accumulated that the cytokine
TNF is a crucial factor in the initiation of the septic syn-
drome (2) . In addition, several in vitro studies indicate that
TNFmaybe an important factor in the hemostatic disbalance
observed in septicemia (3-6). Investigations in cancer patients
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infused with recombinant TNF revealed an activation of both
the coagulation and fibrinolytic system (7-9) . However, the
absence of sequential measurements, the heterogeneity of the
study populations, and the preexistent subclinical activation
ofboth the coagulation and fibrinolytic system hampers proper
evaluation of the balance between these opposite pathways .
We have recently shown in a crossover saline-controlled
study in six healthy men that a single intravenous injection
of recombinanthumanTNF induced activation of the coagu-
lation system that persisted for >6 h, (10) . In the present
investigation, performed simultaneously with the coagula-
tion study, we monitored the fibrinolytic changes after in-
jection of TNF . We then compared the time course of the
fibrinolytic response to TNF with its procoagulant effects
to hypothesize about the mechanism of the frequently ob-
served extensive deposition of thrombi in the microvascula-
ture of multiple organs in patients with septicemia .
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Study Design.
￿
The study was approved by the institutional re-
search and ethics committees and written informed consent was
obtained from all volunteers . The present study was done simul-
taneously with an investigation on the coagulative effects ofTNF
ofwhich the results have been published previously (10) . Six healthy
male volunteers (age 27-33 yr) participated in the study. Each sub-
ject was studied twice with an interval of at least 3 wk; once after,
a bolus intravenous injection of recombinant human TNF of 50
ftg/m2 (Boehringer Ingelheim, Ingelheim am Rhein, Germany),
and once after, an equivalent volume of isotonic saline was ad-
ministered.
Sampling and Assays.
￿
Blood samples were obtained by separate
venipunctures . Blood (9 vol) for the measurement ofPA activity,
urokinase type plasminogen activator (u-PA) antigen, t-PA antigen,
plasminogen activity, D-dimer and ace-antiplasmin activity were
collected in plastic syringes containing 3.2% sodium citrate (1 vol) .
Blood for the determination ofPAM antigen was collected in plastic
syringes loaded with the following anticoagulant : 270mM EDTA,
1.9 mM Na2C03, 282 nmol/liter prostaglandin E ) , and 30mM
theophyline . For the measurement of plasmin-a2-antiplasmin
(PAP) complexes, t-PAPAI-1 complexes, and u-PA-PAI-1 complexes
blood was collected in in siliconized Vacutainer tubes (Becton Dick-
inson & Co ., Plymouth, England) to whichEDTA (10 mM) and
Polybrene (0.05 percent ; wt/vol) were added .
PA activity was measuredby an amidolytical assay (11) . The results
are expressed as a percentage of pre-infusion PA activity. u-PA an-
tigen, t-PA antigen, PAM antigen, and D-dimer were measured
with ELISAs (12-14) . t-PA-PAI-1 and u-PA-PAI-1 complexes were
determined with specific RIAs . Plasminogen activity and a 2 -
antiplasmin activity were measuredby automated amidolytic tech-
niques (15) . The results are expressed as percentages of normal.
PAP complexes were determined by RIA (16) .
Statistical Analysis.
￿
Values are given as means ± SEM . Differ-
ences in resultsbetween theTNF and saline experiments were tested
by analysis of variance (ANOVA) and Newman-Keul's test for mul-
tiple comparison, as indicated .
Results
Stimulation and Inhibition o .fPlasminogen Activation (Fig. 1) .
TNF induced an early, brief increase in overall plasma PA
activity. PlasmaPA activity was already significantly increased
in the first blood sample taken afterTNF injection, i.e., after
15 min, and reached a maximum after 1 h (438 ± 13% ;
p< 0.0001 by ANOVA) . Thereafter, plasma PA activity rap-
idly declined, returning to control values after 5 h . The in-
crease in plasma activity coincided with rises in the plasma
concentrations of u-PA antigen and t-PA antigen . u-PA an-
tigen showed a modest increase from 3.4 ± 0.3 to 5.6 ±
0.4 ng/ml at 45 min (p < 0.0001 by ANOVA) . Plasma t-PA
antigen rose markedly from 4.0 ± 0.9 ng/ml to amaximum
of 84.8 ± 15.9 ng/ml after 3 h (p < 0.0001 by ANOVA) .
The plasma levels of PAI-1 did not change in the first hour
after TNF administration . Thereafter, a steep increase inPAM
antigen values was registered (occurring simultaneously with
the decrease in plasmaPA activity) with a peak after 3 h (from
4.9 ± 1.0 to 39.4 ± 7.8 ng/ml; p < 0.0001 by ANOVA) .
The plasma concentrations ofu-PAPAl-1 complexes did not
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change after TNF injection (data not shown) . t-PAPAI-1 com-
plexes rose afterTNF administration peaking after 2 h (from
0.07 ± 0.02 to 0.67 ± 0.13 nmol/liter, p < 0.0001 by
ANOVA) . Plasma plasminogen activity was not significantly
affected by TNF injection (data not shown) .
Plasmin Activity and Inhibition (Fig . 2).
￿
TNF administra-
tion elicited a steep increase in D-dimer plasma levels, reaching
a summit after 1 h (from 81 ± 9 to 1,091 ± 257 Ag/ml ;
p < 0.0001 byANOVA) . PAP complexes rose transiently after
TNF injection, peaking after 45min (from 3.1 ± 0.7 to 112.7
± 25.2 nmol/liter, p < 0.0001 by ANOVA), while a2-
antiplasmin activity transiently decreased, reaching a nadir
after 45 min (from 88 ± 3% to 73 ± 3% ; p < 0.01 by
ANOVA) .
Discussion
The findings of this study are compatible with enhanced
fibrinolytic activity mainly in the first 2 h after TNF injec-
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Figure 1 .
￿
Stimulation and inhibi-
tion ofplasminogen activation. Mean
(± SEM) plasma levels of indexes of
stimulation and inhibition ofplasmin-
ogen activation after intravenous bolus
injections of recombinant human
TNF (50 Ftg/m2; filled circles) or an
equivalent volume of isotonic saline
(open circles) : PA activity, u-PA an-
tigen, t-PA antigen, PAI-1 antigen,
and t-PA-PAI-1 complexes . Asterisks
indicate statistical significance for the
comparison ofTNF with saline (p<
0.05 by Newman-I{eul's test for mul-
tiple comparison) .x
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tion . Our study confirms and extends previous uncontrolled
investigations in cancer patients infused with TNF . Silverman
et al. (8) registered subsequent increases in plasma t-PA an-
tigen and PAI activity, associated with a transient stimula-
tion of plasma PA activity as determined in one patient. Van
Hinsbergh et al . (9) measured several indexes of fibrinolysis
at 3 and 24 h after the start of a continuous 24-h intravenous
TNF infusion and found sustained elevations in t-PA antigen
andPAI activity. In contrast to our study, u-PA antigen levels
were not affected by TNF administration, which may have
been related to the relative late blood sampling . The plasma
levels of fibrin degradation products were elevated at the end
of the TNF infusion . Remarkably, this increase was not sig-
nificant after 3 h, which sharply contrasts with the early stim-
ulation of fibrinolysis observed in our study (9) . Factors that
may have contributed to this apparent discrepancy include
differences in the way of TNF administration (continuous
infusion vs . bolus injection) and differences in the subjects
under investigation (cancer patients vs. healthy humans). With
respect to the latter possibility, it is noteworthy that patients
with cancer often have subclinical activation ofboth the coagu-
lation system and the fibrinolytic system (7-9) .
The mechanisms underlying the in vivo effects of TNF
on the fibrinolytic system are not elucidated by our study.
In cultures ofhuman endothelial cells, TNF decreases t-PA
release (4), while high concentrations of TNF have been
reported to increase t-PA secretion (6) . u-PA and PAI-1 produc-
tion are stimulated by TNF (4, 6, 17) . However, all these
TNF-induced changes in in vitro systems are detected only
731
Figure 2 .
￿
Plasmin activity and
inhibition. Mean (± SEM) plasma
levels ofindexes ofplasmin activity
and inhibition after intravenous
bolus injections of recombinant
human TNF (50 Rg/m2, filled
circles) or an equivalent volume
of isotonic saline (open circles) :
D-dimer, PAP complexes, and
a 2-antiplasmin activity. Asterisks
indicate statistical significance for
the comparison ofTNF with sa-
line (p <0.05 by Newman7s Keul's
test for multiple comparison) .
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after several hours, and can therefore not properly explain
the rapid in vivo fibrinolytic response observed in our study.
Also, the possible involvement of secondary mediators in-
duced by TNF remains speculative . IDl reduces t-PA release
and stimulates u-PA and PAI-1 production by cultured en-
dothelial cells (4, 17, 18), whereas thrombin increases both
t-PA and PAI-1 secretion under the same experimental con-
ditions (19) . However, these effects, as for those provoked
by TNF, occur relatively slowly. The rapidity by which the
fibrinolytic system is activated after TNF injection as seen
in this study ismore suggestive for an effusion of stored plas-
minogen activators, probably from the vascular endothelium .
Interestingly, previous studies investigating the in vivo
fibrinolytic response to intravenous endotoxin in healthy
humans showed comparable results in our study after TNF
injection, with the important difference that the TNF-induced
changes were detected 1-2 h earlier (20, 21) . Since this in-
terval is identical to the time in which serum TNF reaches
peak values after injection of endotoxin (21), these combined
data strongly implicateTNF as an intermediate factor in the
fibrinolytic changes in endotoxemia and septicemia .
We have recently reported the time course of the activa-
tion of the coagulation system after injection ofTNF in the
same volunteers (10) . TNF induced a rapid activation of factor
X, peaking after 45 min, followed by a gradual generation
of thrombin as reflected by elevated plasma concentrations
of the prothrombin activation peptide F1+2, becoming ap-
parent after 2 h and persisting for 6-12 h (10) . This slow
and sustained thrombin formation contrasts with the presently
described fibrinolytic response characterized by profound ac-
tivation in the first hour postinjection, followed by a fast in-
hibition. Direct comparison o£the dynamics ofprocoagulant
and fibrinolytic effects of TNF in our study subjects reveals
that fibrinolysis was stimulated before significant thrombin
generation could be detected in plasma, which, however, does
not exclude thrombogenesis at the microvascular-endothelial
level as an initiating event in the observed fibrinolytic response.
Still, our findings challenge the putative role of fibrinolysis
as a reactive process protecting against intravascular coagula-
tion . Moreover, when prothrombin activationbecame max-
imal, fibrinolysis was already offset . The highly different time
courses ofthe fibrinolytic and coagulative responses to intra-
venous TNF led us to hypothesize that a net procoagulant
statemay exist several hours after TNF injection . This remark-
able disbalance in the procoagulant and fibrinolytic mecha-
nism may be ofimportance for our understanding of the ten-
dency towards microvascular thrombosis in septicemia.
In conclusion, this controlled study demonstrates that in-
travenous injection ofTNF induces a rapid activation and
a subsequent inhibition of the fibrinolytic system in healthy
humans . Our results, taken together with the data obtained
in the coagulation study (10), suggest that excessive release
of TNF into the circulation, precipitated by invading bac-
teria early in the course of septicemia, may play an important
part in the ensuing development of a disbalance between co-
agulant and fibrinolytic mechanisms, eventually resulting in
microvascular thrombosis .References
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